NCT02246231 is a NA clinical trial of MR imaging in Neurofibromatosis Type 2, sponsored by Manchester University NHS Foundation Trust.

Who is sponsoring NCT02246231?

NCT02246231 is sponsored by Manchester University NHS Foundation Trust.

What drugs are being tested in NCT02246231?

Interventions in NCT02246231: MR imaging.

What condition does NCT02246231 study?

NCT02246231 studies Neurofibromatosis Type 2.

Is NCT02246231 still recruiting?

NCT02246231 is currently completed. Last updated 17 March 2020.

Last reviewed 2020-03-17 · How we verify

NCT02246231

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Implant Position on Magnetic Resonance Image Distortion

Completed NA Last updated 17 March 2020

What this trial tests

NA trial testing MR imaging in Neurofibromatosis Type 2 in 5 participants. Completed in 31 January 2015.

Timeline

3 February 2014

Primary endpoint
31 January 2015

31 January 2015

Quick facts

Lead sponsor	Manchester University NHS Foundation Trust
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	5
Start date	3 February 2014
Primary completion	31 January 2015
Estimated completion	31 January 2015
Sites	1 location across United Kingdom

Drugs / interventions tested

MR imaging

Conditions studied

Neurofibromatosis Type 2 — all drugs for Neurofibromatosis Type 2 →

Sponsor

Manchester University NHS Foundation Trust

Who can join

18 and older, any sex, with Neurofibromatosis Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with Neurofibromatosis type 2 (NF2) almost always develop acoustic neuromas in both ears. As a result of the tumours themselves or the treatment of the tumours, many patients become profoundly deaf in both ears. It is possible to restore a degree of hearing by placing a hearing implant in the brainstem adjacent to the hearing pathways within the brain. This is termed an auditory brainstem implant (ABI). The aim of this study is to find the optimum head position in relation to the MRI magnet field, which would produce least area of image distortion in patients with ABIs. This will be of benefit in optimising the MR imaging in future patients with implants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of MR imaging

Trials testing the same drug.

NCT04394052 — Novel Imaging Techniques for the Characterization of Musculoskeletal Tumors II · recruiting
NCT03766880 — MR-based Models for Clinically Significant Portal Hypertension in Cirrhosis (CHESS1802) · NA · completed
NCT03458520 — Pediatric PET/MR Image Registry · recruiting
NCT03055455 — Neuroimaging and Neuromonitoring in Critically Ill Children With Sepsis · completed

Other recruiting trials for Neurofibromatosis Type 2

Currently open trials in the same condition.

NCT04374305 — Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) · Phase 2 · active not recruiting
NCT01552434 — Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced · Phase 1 · active not recruiting

Other Manchester University NHS Foundation Trust trials

Trials by the same sponsor.

NCT07057284 — DENTOFACIAL-PBT Stage 2 - Feasibility Study · enrolling by invitation
NCT06972238 — Glucose Levels in Acute Pancreatitis and the Impact of Insulin Depletion and Bacterial Endotoxaemia · not yet recruiting
NCT06681545 — Exploring the Lived Experience of Young Adults With Severe Asthma · recruiting
NCT07049263 — Disparities In Access to the Northwest Ambulance Service During Pregnancy, Birth and Postpartum Period and Its Associati · active not recruiting
NCT06561334 — Spasmodic Dysphonia Interviews · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02246231 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Manchester University NHS Foundation Trust
Last refreshed: 17 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02246231.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing